尿激酶型纤溶酶原激活物在乳腺癌中的表达及意义

目的 研究尿激酶型纤溶酶原激活物（ｕＰＡ）在乳腺癌组织中的表达及其临床意义。方法 应用免疫组化ＳＡＢＣ法检测１００例原发性乳腺癌患者中的ｕＰＡ的表达。结果 １０例乳腺癌患者中，ｕＰＡ高表达５５例，占５５．０％；低表达者４５例，占４５．０％；ｕＰＡ表达与ＴＮＭ分期、淋巴结状况及肿瘤大小相关，与年龄、月经状况、ＷＲ无关。ｕＰＡ高表达者的无病生存期和总生存期低于ｕＰＡ低表达者。单因素分析显示，ｕＰＡ的预

Expression and significance of urokinase type plasminogen activator in breast cancer

Objective To study the expression and clinical significance of urokinase type plasminogen activator (uPA) in breast cancer.Methods Applying streptavidin biotin complex (SABC) immunohistochemical technique, expression of uPA was studied in 100 patients with primary breast cancer.Results There were 55 patients with high uPA expression, and 45 with low expression. There was significant correlation between uPA expression and TNM stage, lymph node status, tumor size. Neither age, menopausal status, nor ER status was significantly related with level of uPA expression Patients with high expression of uPA had significantly shorter disease free survival period and overall survival than did those with low expression of uPA. Univariate analysis showed that uPA as a prognostic factor was of similar magnitude to lymph node status and TNM stage, but stronger than that of ER status and tumor size. uPA was an independent prognostic factor affecting disease free survival and overall survival.Conclusion uPA appears to be a strong and independent biolgic marker for predicting prognosis of breast cancer.